Phase I/Ii Multicenter Clinical Trial of Lenalidomide Maintenance After Allogeneic Hematopoietic Cell Transplant (alloHCT) in Patients With High Risk (HR) Multiple Myeloma (MM)
Biology of Blood and Marrow Transplantation- Netherlands
doi 10.1016/j.bbmt.2012.11.111
Full Text
Abstract
Available in
Date
February 1, 2013
Authors
Publisher
Elsevier BV